^
9h
METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer. (PubMed, Biochim Biophys Acta Mol Cell Res)
METTL3 binds to the c-Myc/WDR5 complex and promotes glycolysis, which plays a powerful role in promoting TNBC progression. Our findings further broaden our understanding of the role and mechanism of action of METTL3, and may open up new therapeutic avenues for effective treatment of TNBC with high c-Myc expression.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • WDR5 (WD Repeat Domain 5) • METTL3 (Methyltransferase Like 3)
|
MYC expression
|
JQ-1 • OICR-9429
11h
17β-Estradiol promotes metastasis in triple-negative breast cancer through the Calpain/YAP/β-catenin signaling axis. (PubMed, PLoS One)
Inhibition of YAP transcriptional activity reversed the effects of E2 on the proliferation, migration, invasion, and β-catenin of TNBC cells. In conclusion, we demonstrated that E2 induced metastasis-related behaviors in TNBC cells and this effect was mediated through the Calpain/YAP/β-catenin signaling pathway.
Journal
|
CCND1 (Cyclin D1) • MMP9 (Matrix metallopeptidase 9)
|
CCND1 expression
11h
Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population. (PubMed, JCO Precis Oncol)
Among patients with surgically resected BrM, a high proportion of those with metastatic triple-negative BC and HR+/HER2- disease have HER2-low BrM with potential to benefit from HER2-targeted therapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
14h
Curcumin Inhibits the PPARδ-p-Akt-GLUT1 Pathway and Ameliorates the Antiproliferative Effects of Doxorubicin in MDA-MB-231 Cells. (PubMed, Asian Pac J Cancer Prev)
Our study demonstrates that regulation of GLUT1 by curcumin via the PPARδ/Akt signaling improves the efficacy of doxorubicin by promoting its growth inhibitory effects in MDA-MB-231 cells.
Journal
|
SLC2A1 (Solute Carrier Family 2 Member 1)
|
doxorubicin hydrochloride
14h
Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer. (PubMed, Asian Pac J Cancer Prev)
Patients with low CD8+, positive PARP, and positive EGFR expressions seem to be associated with poorer overall survival in TNBC. After approximately one year of follow-up, higher survival was observed in patients with high CD8+, negative PARP, and negative EGFR. Staging remains the main predictor of TNBC survival. Therefore, early detection and treatment of TNBC are essential to improve survival.
Journal • PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
EGFR expression • CD8 expression • EGFR positive • EGFR negative • CD8-H • CD8 negative
18h
Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells. (PubMed, Cancer Rep (Hoboken))
Thus, the study suggests that EGFR inhibition-mediated sensitization of the aggressive and metastatic breast CSCs in TNBCs toward chemotherapeutics may reduce the relapse of the disease.
Journal • Cancer stem • Metastases
|
EGFR (Epidermal growth factor receptor) • CD24 (CD24 Molecule)
|
EGFR overexpression
|
doxorubicin hydrochloride
20h
Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models. (PubMed, Int J Mol Sci)
However, the efficacy of DPN treatment decreased when cancer cells were pre-differentiated in the presence of E2. Our results support ERβ as a potential target for the prevention and treatment of BCBM and suggest that targeted vector-based approaches may be effective for future preventive and therapeutic implications.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CLDN5 (Claudin 5)
|
HER-2 positive
20h
Efficacy of Cold Atmospheric Plasma vs. Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review. (PubMed, Int J Mol Sci)
The treatment of TNBC cell lines with CAP proved successful, with apoptosis emerging as the predominant type of cellular death. This systematic review presents a comprehensive overview of the treatment landscape in chemotherapy and CAP regarding their efficacy in TNBC cell lines.
Review • Journal
|
ANXA5 (Annexin A5)
20h
Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice. (PubMed, Int J Mol Sci)
In this study, we investigated whether mEHT accelerates the tumor-specific delivery of doxorubicin (DOX) from lyso-thermosensitive liposomal doxorubicin (LTLD) and improves its anticancer efficacy in mice bearing a triple-negative breast cancer cell line (4T1)...The body weight loss was similar in all mice treated with any DOX formulation, suggesting no difference in toxicity. In conclusion, LTLD combined with mEHT represents a novel approach for DOX delivery into cancer tissue.
Preclinical • Journal
|
CASP3 (Caspase 3)
|
pegylated liposomal doxorubicin • ThermoDox (lyso-thermosensitive liposomal doxorubicin)
20h
Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women. (PubMed, Int J Mol Sci)
Our data indicate that BRCA1 and MGMT epimutations significantly contribute to the development of breast cancer and ovarian cancer in Saudi cancer patients. These blood-based biomarkers could help identify female patients at high risk of developing TNBC and HGSOC at an early age.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
BRCA1 mutation
23h
THZ2 Ameliorates Mouse Colitis and Colitis-Associated Colorectal Cancer. (PubMed, Biomedicines)
Moreover, THZ2 inhibits the development of colorectal cancer in the mouse model of AOM/DSS-induced colitis-associated colorectal cancer. Generally, THZ2 not only can inhibit DSS-induced colitis, but also can hinder AOM/DSS-induced colorectal cancer.
Preclinical • Journal
|
IL6 (Interleukin 6) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDK7 (Cyclin Dependent Kinase 7) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II)
|
PTGS2 expression • IL6 expression
23h
Comparative EPR Studies on the Influence of Genistein on Free Radicals in Non-Irradiated and UV-Irradiated MCF7, T47D and MDA-MB-231 Breast Cancer Cells. (PubMed, Biomedicines)
An increase in the amount of free radicals in UV-irradiated MDA-MB-231 cancer cells was observed with increasing genistein concentration. The antioxidant efficacy of genistein as a potential plant-derived agent supporting the treatment of various cancers may be determined by differences in signalling pathways that are characteristic of breast cancer cell line subtypes and differences in activation of oxidative stress response pathways.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
23h
Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion. (PubMed, Biomedicines)
The movement of the cells through the Matrigel was also inhibited by 74% after PCAIs exposure, which could have been due to the depleted levels of F-actin and vinculin punctate, resulting in the shrinkage of the cells by 76%, thereby impeding cell movement. These results show promise for PCAIs as potential therapies for TNBC as they significantly inhibit the hallmark processes and pathways that promote cell proliferation, migration, and invasion, which result in poor prognoses for breast cancer patients.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • VCL (Vinculin) • BAK1 (BCL2 Antagonist/Killer 1) • RASA1 (RAS P21 Protein Activator 1)
|
RAS mutation
24h
Induction of Oxidative Stress and Ferroptosis in Triple-Negative Breast Cancer Cells by Niclosamide via Blockade of the Function and Expression of SLC38A5 and SLC7A11. (PubMed, Antioxidants (Basel))
Niclosamide decreased the glutathione levels, inhibited proliferation, suppressed GPX4 expression, increased lipid peroxidation, and induced ferroptosis in TNBC cells. It also significantly reduced the growth of the TNBC cell line MB231 in mouse xenografts.
Journal
|
GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
GPX4 expression
1d
TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. (PubMed, Cancers (Basel))
Regarding recurrence-free survival, the prognosis was poor in the TP53 and/or BRCA1 mutation-positive groups, especially in triple-negative breast cancer (TNBC) patients. In conclusion, the results of this study indicate that ctDNA with liquid biopsy could identify the poor prognosis group before treatment among TNBC patients and for those for whom optimal treatment selection is desirable; additionally, optimal treatment could be selected according to the ctDNA analysis results.
Journal • BRCA Biomarker • Circulating tumor DNA
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
TP53 mutation • BRCA1 mutation • HR negative
1d
A Retrospective View of the Triple-Negative Breast Cancer Microenvironment: Novel Markers, Interactions, and Mechanisms of Tumor-Associated Components Using Public Single-Cell RNA-Seq Datasets. (PubMed, Cancers (Basel))
The overexpression of DSC2 in TNBC and its prognostic power were verified by using METABRIC, a large bulk RNA-seq dataset with clinical information. These findings not only corroborate previous hypotheses but also lay the foundation for a new structural understanding of TNBC, as revealed through our single-cell analysis workflow.
Retrospective data • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DSG2 (Desmoglein 2)
1d
Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets. (PubMed, Cancers (Basel))
In this article, we introduce ATR and CHK1/2 inhibitors as promising therapeutic approaches for the management of TNBC. Preclinical and clinical studies performed evaluating ATR and CHK1/2 inhibitors for the treatment of TNBC and associated challenges encountered in this context to date are reviewed.
Review • Journal
|
CHEK1 (Checkpoint kinase 1)
1d
Retrospective Observational Study to Determine the Epidemiology and Treatment Patterns of Patients with Triple-Negative Breast Cancer. (PubMed, Cancers (Basel))
We observed a significant increase in the use of systemic therapy among TNBCs, whereas carboplatin and dose-dense regimens showed the most prominent upsurge in the neoadjuvant setting. Moreover, the use of neoadjuvants was positively correlated with less invasive breast and lymph node surgeries. The presented data align with general trends observed in other countries and will contribute to expanding knowledge in the planning of treatment regimens and their outcomes.
Observational data • Retrospective data • Journal • BRCA Biomarker
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
carboplatin
1d
NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
P2, N=122, Terminated, National Cancer Institute (NCI) | Active, not recruiting --> Terminated; Inadequate accrual rate
Trial termination • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • ALK mutation
|
Lynparza (olaparib) • Recentin (cediranib)
1d
ASCENT-J02: Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=143, Recruiting, Gilead Sciences | Trial primary completion date: Apr 2025 --> May 2026
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • EGFR positive
|
Trodelvy (sacituzumab govitecan-hziy)
1d
KEYNOTE-877: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
P1/2, N=323, Active, not recruiting, RAPT Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • tivumecirnon (FLX475)
1d
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. (PubMed, Mol Cancer)
Our findings uncover LINC00115 as a critical regulator of BCSC and highlight targeting LINC00115 and SETDB1 as a potential therapeutic strategy for chemotherapeutic resistant breast cancer.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
HIF1A expression
|
paclitaxel
1d
Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation. (PubMed, Anticancer Res)
Patients with triple-negative bone metastatic breast cancer showed unfavorable survival. Primary tumor resection prolonged survival in each subtype except for HR-/HER2+.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
1d
Synchronized Chemotherapy/Photothermal Therapy/Sonodynamic Therapy of Human Triple-Negative and Estrogen Receptor-Positive Breast Cancer Cells Using a Doxorubicin-Gold Nanoclusters-Albumin Nanobioconjugate. (PubMed, Ultrasound Med Biol)
Results of the MTT assay, detection of the generation of intracellular reactive oxygen species and occurrence of apoptosis in the cells confirmed that CTX/PTT/SDT by Dox-AuNCs-BSA was attained with lower needed doses of the drug and improved tumor cell ablation, which would result in the enhancement of therapeutic efficacy and overcoming of therapeutic resistance.
Journal
|
ER (Estrogen receptor)
|
ER positive
|
doxorubicin hydrochloride
1d
Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy. (PubMed, Mol Pharm)
First, the bromodomain-containing protein 4 (BRD4) inhibitor JQ1 and the cyclooxygenase-2 (COX-2) inhibitor celecoxib (CXB) were coloaded into chondroitin sulfate (CS) to obtain CS@JQ1/CXB nanoparticles (NPs). Combination treatment exhibited synergistic cytotoxicity, antimigration ability, and apoptosis-inducing and immune activation effects on TNBC cells and effectively suppressed tumor growth and metastasis in TNBC tumor-bearing mice by activating the tumor immune response and inhibiting angiogenesis. In summary, this study offers a novel combinatorial immunotherapeutic strategy for the clinical TNBC treatment.
Journal • Metastases
|
BRD4 (Bromodomain Containing 4)
|
JQ-1 • celecoxib oral
1d
Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues. (PubMed, Elife)
In this study, we utilized a microfluidic device to induce the development of doxorubicin-resistant (DOXR) cells from triple negative breast cancer (TNBC) cells within 11 days by generating gradients of DOX and medium. In vivo chemoresistant xenograft models, an unbiased genome-wide transcriptome analysis, and a patient data/tissue analysis all showed that chemoresistance arose from failed epigenetic control of the nuclear protein-1 (NUPR1)/histone deacetylase 11 (HDAC11) axis, and high NUPR1 expression correlated with poor clinical outcomes. These results suggest that the chip can rapidly induce resistant cells that increase tumor heterogeneity and chemoresistance, highlighting the need for further studies on the epigenetic control of the NUPR1/HDAC11 axis in TNBC.
Journal
|
HDAC1 (Histone Deacetylase 1) • HDAC11 (Histone Deacetylase 11) • NUPR1 (Nuclear Protein 1 Transcriptional Regulator, Candidate Of Metastasis 1)
|
NUPR1 expression
|
doxorubicin hydrochloride
1d
Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification. (PubMed, Diagnostics (Basel))
The results of this study significantly singled out the luminal A subtype, and among them classic ILC, as the subtype with the most favorable expression ratio of the investigated predictive/prognostic immunohistochemical markers.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • PGR expression
2d
Suppressor of cytokine signaling-3 expression and its regulation in relation to inflammation in Chronic Obstructive Pulmonary Disease. (PubMed, Front Immunol)
Expression of SOCS3 in BAL macrophage-derived EVs might be useful to assess the degree of inflammation and possible progression of COPD. Downregulation of SOCS3, by miRNA, in smokers without COPD might contribute to the risk of developing cancer in these patients.
Journal
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD14 (CD14 Molecule) • MIR221 (MicroRNA 221) • SOCS3 (Suppressor Of Cytokine Signaling 3)
2d
Transmembrane protein 25 abrogates monomeric EGFR-driven STAT3 activation in triple-negative breast cancer. (PubMed, MedComm (2020))
In wild-type cells, TMEM25 physically associates with EGFR monomer and suppresses the EGFR-mediated STAT3 phosphorylation, which results in the sequestration of unphosphorylated STAT3 in the cytoplasm. In TMEM-/- cells, EGFR monomer phosphorylates STAT3 at the basal level.
Journal
|
EGFR (Epidermal growth factor receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3)
2d
Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies. (PubMed, J Exp Clin Cancer Res)
Our study proposes smart, novel and safe multifunctional nanoplatforms simultaneously addressing cancer-stroma within the tumor microenvironment, which are: (i) actively delivered to the targeted cells through highly specific aptamers; (ii) localized by means of their luminescence, and (iii) activated via minimally invasive light, launching efficient tumor death, thus providing innovative precision therapeutics. Given the unique features, the proposed dual targeted nanoformulations may open a new door to precision cancer treatment.
Journal • Stroma
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta)
|
HER-2 positive • EGFR positive
2d
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy (clinicaltrials.gov)
P2, N=120, Suspended, Vanderbilt-Ingram Cancer Center | Recruiting --> Suspended
Trial suspension • Circulating tumor DNA • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
Trodelvy (sacituzumab govitecan-hziy)
2d
Trial completion • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • PGR expression
|
AiRuiKa (camrelizumab)
2d
Ezetimibe inhibits the migration and invasion of triple-negative breast cancer cells by targeting TGFβ2 and EMT. (PubMed, FEBS Open Bio)
Overexpression of TGFβ2 reversed the inhibitory effect of ezetimibe on the migration and invasion of breast cancer cells. Taken together, our results suggest that ezetimibe might be a potential candidate for the treatment of breast cancer metastasis.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • TGFB2 (Transforming Growth Factor Beta 2)
3d
MOB-CBAM: A dual-channel attention-based deep learning generalizable model for breast cancer molecular subtypes prediction using mammograms. (PubMed, Comput Methods Programs Biomed)
This study presents lightweight MOB-CBAM, a novel deep learning framework, to address breast cancer diagnosis and subtype prediction. The model's innovative incorporation of the CBAM enhances precise predictions. The extensive evaluation of the CMMD dataset and cross-validation on other datasets affirm the model's efficacy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
3d
Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR. (PubMed, Discov Med)
The findings of this study suggest both activity and safety for the combination of chemotherapy and the mTOR inhibitor everolimus (CT+EVE) in patients with HER2- mBC who have alterations in the PI3K pathway, particularly those who have received fewer prior chemotherapy. However, it is crucial to note that large-scale, randomized control studies are warranted to more comprehensively characterize the efficacy and safety of this combination therapy.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NF1 (Neurofibromin 1) • CDK4 (Cyclin-dependent kinase 4)
|
HR positive • HER-2 negative • NF1 mutation
|
everolimus • vinorelbine tartrate
3d
SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation. (PubMed, J Cell Mol Med)
Fer-1, GSH and Vitamin C attenuated the effects but not erastin...Similarly, it significantly increases the expression of SAT1, ALOX5, ALOX15, ALOXE3 and CHAC1 that, promoting ferroptosis while downregulating the NFE2L2 gene and protein that inhibit ferroptosis. SBFI26 leads to cellular accumulation of fatty acids, which triggers excess ferrous ions and subsequent lipid peroxidation for inducing ferroptosis.
Journal
|
HMOX1 (Heme Oxygenase 1) • ALOX15 (Arachidonate 15-Lipoxygenase) • ALOX5 (Arachidonate 5-Lipoxygenase) • ALOXE3 (Arachidonate Lipoxygenase 3) • CHAC1 (ChaC Glutathione Specific Gamma-Glutamylcyclotransferase 1) • FABP5 (Fatty Acid Binding Protein 5)
|
HMOX1 expression
|
erastin
3d
PROM2 overexpression induces metastatic potential through epithelial-to-mesenchymal transition and ferroptosis resistance in human cancers. (PubMed, Clin Transl Med)
Our results open the way for further studies using PROM2 as a bio-target in resort situations in human metastatic melanoma and also in other cancer types.
Journal • Metastases
|
PROM2 (Prominin 2)
3d
Patient-reported symptoms before adjuvant locoregional radiotherapy for breast cancer: triple-negative histology impacts the symptom burden. (PubMed, Strahlenther Onkol)
Different surgical strategies, age, and body mass index did not impact on ESAS scores, while the type of adjuvant systemic therapy did. The effect of previous neoadjuvant treatment and unfavorable tumor biology (triple negative) emerged as important factors associated with symptom burden, albeit in different domains. ESAS data may facilitate identification of patients who should be considered for additional supportive measures to alleviate specific symptoms.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
3d
Pharmacological suppression of the OTUD4-CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. (PubMed, J Clin Invest)
In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-L1 therapy. Collectively, our findings uncover a novel strategy for targeting immunosuppressive OTUD4-CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto) • TGFB1 (Transforming Growth Factor Beta 1) • TRIM21 (Tripartite Motif Containing 21)
|
CD73 expression
3d
Elevated MMP1 Expression in Carcinoma-Associated Fibroblasts of Breast Cancer Contributes to Tumor Progression and Unfavorable Prognosis. (PubMed, Ann Clin Lab Sci)
The results indicated that MMP1 expression in CAFs may participate in the malignant phenotype and unfavorable prognosis of breast cancer.
Journal
|
MMP1 (Matrix metallopeptidase 1)
|
MMP1 overexpression
|
docetaxel
3d
Ribociclib and Bicalutamide in AR+ TNBC (clinicaltrials.gov)
P1/2, N=37, Recruiting, Kari Wisinski | Trial primary completion date: Jan 2024 --> May 2024
Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)
|
HER-2 negative • AR positive
|
Kisqali (ribociclib) • bicalutamide
3d
Activation of ERβ hijacks the splicing machinery to trigger R-loop formation in triple-negative breast cancer. (PubMed, Proc Natl Acad Sci U S A)
In this study, we demonstrated that a specific ERβ agonist, LY500307, potently induces R-loop formation and DNA damage in TNBC cells...In clinical samples including 115 patients from The Cancer Genome Atlas (TCGA) and 32 patients from an in-house cohort, we found a close correlation in the expression of ESR2 and U2AF1 in TNBC patients. Collectively, our study has unraveled the molecular mechanisms that explain the therapeutic effects of ERβ activation in TNBC, which provides rationale for ERβ activation-based single or combined therapy for patients with TNBC.
Journal • PARP Biomarker
|
ER (Estrogen receptor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)